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Introduction {#sec1}
============

Hemophilia A (HA) is one of the most common inherited bleeding disorders, with an incidence of 1 in 5,000 males worldwide ([@bib1]). HA is caused by various genetic mutations (2,015 unique variants) within the X-linked coagulation *factor VIII* (*FVIII*) gene, including large deletions, insertions, inversions, and point mutations (FVIII variant database; [www.factorviii-db.org/](http://www.factorviii-db.org/){#intref0010}). At present, the intravenous infusion of recombinant FVIII protein is an available treatment option; however, this therapy is not curative and is associated with high costs, lifelong treatment, and the formation of FVIII-inactivating antibodies. Thus, the development of a fundamental method for treating HA is required.

Human induced pluripotent stem cells (iPSCs) are a versatile cell source for transplanting autologous cells with restored genes to compensate for mutated genes, for understanding cellular and molecular disease mechanisms and disease modeling ([@bib2]), and for therapeutic applications including drug discovery ([@bib20]). Indeed, autologous retinal pigment epithelial cells differentiated from iPSCs were transplanted into a patient with neovascular age-related macular degeneration ([@bib9]). In addition, patient iPSCs were used for genome editing to correct genetic mutations ([@bib8], [@bib11], [@bib24]).

The type II clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system is a versatile tool for genome editing ([@bib6]). Recently, nuclease-mediated genome editing was performed in HA patient iPSCs to correct the endogenous *FVIII* locus to the normal gene orientation without using ectopic donor DNA or with the targeted insertion of donor DNA harboring partial *FVIII* exons ([@bib12], [@bib23]), strategies that are typically applied to inversion mutations. Interestingly, more than 60% of HA patients exhibit other genetic variations including point mutations, large deletions, insertions, or duplications ([@bib4]), which suggests that the application of a universal correction strategy is required for all types of genetic variations that occur in HA. In addition, protocols to differentiate iPSCs into liver sinusoidal endothelial cells (LSECs), which are the primary producers of the FVIII protein, have also not been available to date ([@bib13]). Thus, to overcome these limitations we have developed a universal correction approach by accessing a genomic safe harbor site and expressing functional FVIII without any restrictions in the type of variation or the cell type used for transplantation.

In this study, we chose the human *H11* locus as a safe harbor site and inserted the functional *FVIII* gene into this site using the CRISPR/Cas9 system in a targeted manner in both deleted- and inverted-patient iPSCs. Importantly, we found that the mRNA expression induced FVIII activity in the cultured supernatants. Moreover, we demonstrated that no off-target mutations were found in the corrected clones. To our knowledge, this is the first report to demonstrate a targeted *FVIII* insertion in a safe harbor locus that resulted in the phenotypic correction of the *FVIII* deficiency in HA patient iPSCs. This approach may provide a universal correction method for application to all types of genetic variations found in HA patients.

Results {#sec2}
=======

Generation of *FVIII* Deleted Patient iPSCs {#sec2.1}
-------------------------------------------

First, we derived *FVIII* deleted iPSC clones from adipose tissue-derived mesenchymal stem cells obtained from a patient diagnosed with several exon deletions (exons 8--22) using episomal vectors. We selected a total of nine embryonic stem cell-like colonies (termed Epi1 to Epi9), which were maintained onto a feeder layer followed by adaptation in feeder-free culture conditions ([Figure S1](#mmc1){ref-type="supplementary-material"}A). After seven passages, we confirmed the absence of the episomal vectors in all the clones except one by PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}B). For the remaining experiments we chose the Epi6 line, which does not contain the *EBNA-1* sequence encoded in the vectors and expresses pluripotency markers including SSEA4, TRA-1-60, OCT4, NANOG ([Figure S1](#mmc1){ref-type="supplementary-material"}C), *SOX2*, and *Lin28* ([Figure S1](#mmc1){ref-type="supplementary-material"}D). The ability to differentiate *in vitro* was further confirmed in the Epi6 line ([Figure S1](#mmc1){ref-type="supplementary-material"}E), which also exhibited a normal karyotype ([Figure S1](#mmc1){ref-type="supplementary-material"}F).

Synthetic Single Guide RNA Design and Validation of Nuclease Activity {#sec2.2}
---------------------------------------------------------------------

To insert *FVIII* into the *H11* locus using a targeted approach, we designed the synthetic single guide RNA (sgRNA) that recognized the target site using web-based *in silico* tools ([crispr.mit.edu](http://crispr.mit.edu){#intref0015}) ([Figure 1](#fig1){ref-type="fig"}A). We co-transfected either HEK-293T cells or each iPSC clone with both Cas9 and sgRNA vectors. To test the nuclease activity, we performed a T7 endonuclease I (T7E1) assay. The nuclease activity was relatively high, inducing small insertions and deletions (indels) mutations with a frequency of 15% at the *H11* locus based on the T7E1 assay results ([Figure S2](#mmc1){ref-type="supplementary-material"}A). However, the nuclease activity in each iPSC clone was relatively low due to low transfection efficiency, inducing indels with a frequency of 4% and 4.3%, respectively ([Figure S2](#mmc1){ref-type="supplementary-material"}A). In addition, deep sequencing analyses revealed that the frequency of indels at the target site was 27.9% ([Figure S2](#mmc1){ref-type="supplementary-material"}B), with various indels found at the target site ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Moreover, no off-target mutations were detectably induced at eight homologous sites that differed from the on-target site by up to four nucleotides ([Figure S2](#mmc1){ref-type="supplementary-material"}B).Figure 1Targeted Insertions of the *FVIII* Gene into the Human *H11* Locus of HA Patient-Derived iPSCs(A) Schematic overview depicting the *FVIII* gene knockin strategy into the *H11* locus located in human chromosome 22. The bases underlined in blue indicate the sgRNA target site. The protospacer adjacent motif sequence is shown in red. The five specific primers used for genotyping are shown. Lower panel shows PCR-based screening for excision of the selection cassette.(B) PCR-based genotype analysis to confirm the removal of the puromycin expression cassette in the targeted iPSC clones. Black arrowheads indicate the DNA bands containing the puromycin cassette in the inv-K1 and del-K1 clones.(C) Post-excision DNA sequence analysis between the two underlined *loxP* sites.(D) Chromatograms showing the targeted excision of the puromycin cassette from the knockin allele.(E) Droplet digital PCR (ddPCR) analysis to determine the copy number of the inserted fragment in each clone. The *RPP30* gene served as a reference. The primer sequences for the intron 1 locus (Intron 1) of the endogenous *FVIII* gene and for exon 21 to exon 23 (E21--E23) of the knockin donor template are described in the ddPCR analysis section of [Experimental Procedures](#sec4){ref-type="sec"}.See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}; [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Targeted Knockin of the *FVIII* Gene into the Human *H11* Locus {#sec2.3}
---------------------------------------------------------------

In parallel, we cloned the *FVIII* expression cassette under the control of the human elongation factor 1α (EF1α) promoter and a puromycin expression cassette into the backbone vector to construct donor DNA, followed by cloning flanked by both homology arms ([Figures 1](#fig1){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). Thereafter, we electroporated Cas9 ribonucleoproteins (RNPs) and donor DNA into both *FVIII* inverted iPSCs (inv-Pa) and *FVIII* deleted iPSCs (del-Pa). Following additional culturing and puromycin selection, we screened drug-resistant colonies by PCR-based genotyping to find colonies harboring the targeted knockin using the specific primer sets listed in [Table S1](#mmc1){ref-type="supplementary-material"} ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Nine out of 14 colonies (64.3%, in case of inv-Pa) and 18 out of 27 colonies (66.7%) exhibited positive PCR bands for the inv-Pa and del-Pa knockin junctions on an agarose gel, respectively ([Table S2](#mmc1){ref-type="supplementary-material"}). Following three passages, we derived two clones (inv-K1 and inv-K2) from inv-Pa iPSCs and three clones (del-K1 to del-K3) from del-Pa iPSCs, and demonstrated that all of the clones were single-allele knockin clones ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Targeted knockins from all the clones were further verified by Sanger sequencing of PCR amplicons ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). Next, to excise the puromycin expression cassette from the clones, we chose the inv-K1 and del-K1 clones because they had no indels, even in the untargeted allele (−KI allele) ([Figure S3](#mmc1){ref-type="supplementary-material"}C). After the transient expression of *Cre* recombinase in these clones, we screened seven colonies by PCR-based genotyping using the F3/R2 primers ([Figure 1](#fig1){ref-type="fig"}A). The successful excision of the selection cassette was confirmed by PCR-based genotyping using specific primers ([Figure 1](#fig1){ref-type="fig"}B and [Table S1](#mmc1){ref-type="supplementary-material"}). Following the verifications of recombination between the two *loxP* sites by Sanger sequencing ([Figures 1](#fig1){ref-type="fig"}C and 1D), we derived the three puromycin-excised clones (inv-K1e1 to inv-K1e3) from the inv-K1 clone, and the two clones (del-K1e1 and del-K1e2) from the del-K1 clone ([Figure 1](#fig1){ref-type="fig"}B). Next, we confirmed that four knockin clones (inv-K1e1, inv-K1e2, del-K1e1, and del-K1e2) contained only one copy of the *FVIII* knockin fragment using droplet digital PCR analysis ([Figure 1](#fig1){ref-type="fig"}E). These results revealed targeted integration of the *FVIII* gene at the *H11* locus.

Analyses of Pluripotency and Off-Target Mutations in Genetically Corrected Clones {#sec2.4}
---------------------------------------------------------------------------------

Next, we investigated whether the corrected clones maintained their pluripotent characteristics compared with the parental clones. Indeed, all the corrected clones actively transcribed pluripotency genes, including *OCT4*, *SOX2*, and *LIN28* ([Figure 2](#fig2){ref-type="fig"}A), and maintained similar levels of pluripotency marker proteins such as SSEA4, TRA-1-60, OCT4, and NANOG compared with their parental iPSC clones ([Figure 2](#fig2){ref-type="fig"}B). In addition, the corrected clones successfully differentiated into the three germ layers, as shown by positive immunostaining for NESTIN (ectoderm), α-smooth muscle actin (mesoderm), and hepatocyte nuclear factor-3β (endoderm) ([Figure 2](#fig2){ref-type="fig"}C). Furthermore, the clones exhibited a normal 46, XY karyotype by G-banding ([Figure 2](#fig2){ref-type="fig"}D). We then confirmed by qPCR analysis that no significant differences were found in the expression levels of *DRG1* and *EIF4ENIF1* genes between the parental and knockin iPSC clones ([Figure 2](#fig2){ref-type="fig"}E). No PCR bands corresponding to the *Cre* sequence were amplified from each knockin clone ([Figure 2](#fig2){ref-type="fig"}F). We then investigated whether off-target mutations were induced in the corrected clones by the nuclease used in this study. Ten potential off-target sites were examined by targeted deep sequencing in the four corrected clones and the two types of parental clones. We verified that no significant off-target mutations were induced at the sites listed in [Table S3](#mmc1){ref-type="supplementary-material"} ([Figure S4](#mmc1){ref-type="supplementary-material"}). To further verify off-target mutations, we performed whole-genome sequencing analysis for three iPSC clones (del-Pa, del-K1e1, and del-K1e2) using Illumina NovaSeq6000 and yielding 40× coverage. We demonstrated that no off-target mutations were found ([Table S4](#mmc1){ref-type="supplementary-material"}). These results revealed that the nuclease used in this study did not induce off-target mutations in two of the knockin clones, which is in line with a recent study demonstrating the high specificity of Cas9-mediated nuclease in the clonal populations of pluripotent stem cells ([@bib12], [@bib22]).Figure 2Analyses of Pluripotency from the Corrected iPSC Clones(A) Expression of endogenous *OCT4*, *SOX2*, and *LIN28* in parental patient and corrected iPSC clones. The expression level of each gene was normalized to that of *GAPDH*. Data are means ± SEM of three independent experiments.(B) Expression of the pluripotency markers OCT4, NANOG, SSEA-4, and TRA-1-60 detected by immunocytochemistry. The DAPI signal indicates the total cell content in the image. Scale bars, 200 μm.(C) Expression of marker proteins representing the ectoderm (NESTIN), mesoderm (α-smooth muscle actin \[α-SMA\]), and endoderm (hepatocyte nuclear factor-3β \[HNF-3β\]). The DAPI signal indicates the total cell content in the image. Scale bars, 100 μm.(D) Karyotype analyses were performed in the corrected iPSC clones.(E) Expression of *DRG1* and *EIF4ENIF1* in parental and corrected patient iPSC clones. The expression level of each gene was normalized to that of *GAPDH*. Data are means ± SEM of three independent experiments.(F) Detection of the *Cre* expression vector sequence remaining in each clone by PCR. The *GAPDH* gene was used as a quality control for the total isolated DNA. Total DNA isolated from the cells 3 days after electroporation was used as the positive control for the *Cre* expression vector.

Phenotypic Correction of the FVIII Deficiency *In Vitro* {#sec2.5}
--------------------------------------------------------

After the successful targeted insertion of the *FVIII* gene in the *H11* locus, we examined the phenotype of the corrected clones using an *in vitro* culture system. Using semiquantitative RT-PCR, the *FVIII* mRNA expression levels in the *H11* locus were measured at the undifferentiated stage. As expected, no PCR bands corresponding to *FVIII* exons 21 and 23 were amplified from the two types of patient iPSCs due to either incorrect splicing (inv-Pa) or deletion of the corresponding region (del-Pa); however, corresponding bands to *FVIII* exons 6 and 7 were amplified from both inv-Pa and del-Pa iPSC clones ([Figure 3](#fig3){ref-type="fig"}A). In contrast, PCR bands corresponding to exons 21 and 23 were amplified in the corrected iPSCs, and were detected regardless of the presence or absence of the selection cassette ([Figure 3](#fig3){ref-type="fig"}A). We also performed Sanger sequencing to verify the sequences of the amplified DNA bands ([Figure 3](#fig3){ref-type="fig"}B). In additional qPCR analyses, we demonstrated that there were no differences in the expression of the *FVIII* gene between each post-excision clone (inv-K1e1 to inv-K1e3, or del-K1e1 and del-K1e2) ([Figure 3](#fig3){ref-type="fig"}C). We then investigated whether the induction of *FVIII* expression corresponded to increased FVIII activity in the corrected clones. As shown in [Figure 3](#fig3){ref-type="fig"}D, all of the corrected clones, regardless of whether they had the selection cassette, exhibited highly elevated FVIII activity levels compared with levels in the parental patient iPSCs.Figure 3Phenotypic Rescue of the Expression of *FVIII* Gene from the Corrected iPSC Clones(A) RT-PCR analysis to detect the expression of *FVIII* and *OCT4* in undifferentiated, corrected iPSC clones. *GAPDH* expression was used for normalization.(B) Chromatograms showing the sequences of amplified DNA bands from each clone (related to A).(C) Results of the qPCR analysis showing the *FVIII* expression levels in undifferentiated patient iPSC clones and corrected clones. *GAPDH* expression was used for normalization. Data are means ± SEM of three independent experiments. ND, not detected.(D) The FVIII activity was determined after 20-fold concentration in supernatants obtained from either patient or corrected clones. Data indicate activity detected per 1 × 10^6^ iPSCs. Data are means ± SEM of three independent experiments.

Next, the four corrected iPSC clones, including the two types of patient iPSCs, were differentiated into endothelial cells, a source of FVIII production ([@bib19]), as previously reported ([@bib5]). We did not detect any impairment in the differentiation of the clones into endothelial cells, which exhibited cobblestone-like morphologies at the time of differentiation on day 4 ([Figure 4](#fig4){ref-type="fig"}A) and positive staining for endothelial cell markers such as CD31 and von Willebrand factor (vWF) at the end of differentiation ([Figure 4](#fig4){ref-type="fig"}B). We further evaluated the levels of *FVIII* mRNA using RT-PCR and qPCR. No PCR bands corresponding to *FVIII* exons 21 and 23 were detected in the patient endothelial cells that differentiated from inv-Pa and del-Pa clones ([Figure 4](#fig4){ref-type="fig"}C). However, as expected, the *FVIII* mRNA was detected in endothelial cells differentiated from the corrected iPSC clones ([Figure 4](#fig4){ref-type="fig"}C). In addition, all cells that differentiated from the corrected clones showed significantly elevated FVIII activity levels compared with the patient iPSCs ([Figure 4](#fig4){ref-type="fig"}D). These results indicated that the phenotype of the patient iPSCs could be corrected by the expression of the *FVIII* gene via targeted knockin at the *H11* locus.Figure 4Functional Correction of FVIII Deficiency in Endothelial Cells Differentiated from Corrected iPSC Clones(A) Phase image of cobblestone-like morphologies at the time of differentiation on day 4 in the indicated clones. Scale bars, 200 μm.(B) Expression of marker proteins (CD31 and vWF) representing endothelial cells (ECs) derived from parental patient and corrected clones. The DAPI signal indicates the total cell content in the image. Scale bars, 100 μm.(C) Expression of *FVIII* mRNA including EC marker genes were verified in cells differentiated from patients and corrected clones using RT-PCR (upper panel) and qPCR (lower panel). *GAPDH* expression was used for normalization. Data are means ± SEM of three independent experiments. ND, not detected.(D) The FVIII activity was determined after 20-fold concentration in supernatants obtained from patient or corrected clones after differentiation into ECs. Data indicate activity detected per 1 × 10^6^ ECs. Data are means ± SEM of three independent experiments. ^∗^p \< 0.001 compared with the parental cells (Student\'s t test).

Discussion {#sec3}
==========

In typical genome editing, correcting the endogenous locus itself is an ideal strategy ([@bib14]). However, there are some current limitations to targeting the endogenous site in HA: (1) there are no protocols for differentiating iPSCs into LSECs, which are the primary producers of the FVIII protein; (2) microvascular endothelial cells cannot fully correct the phenotype because they produce only a small amount of FVIII protein; and (3) it is not feasible to prepare sgRNA, including donor DNA, for the 2,015 unique mutations found in HA. To overcome these limitations, we attempted the targeted knockin of the functional *FVIII* gene into a safe harbor site for a universal correction regardless of mutation types. Although there was an attempt to target *FVIII* gene at ribosomal DNA locus in HA patient iPSCs using TALENickases, this attempt has not demonstrated successful functional restoration in an *in vivo* system ([@bib10]).

The *H11* locus was identified as a safe harbor site and used to express transgene in iPSCs ([@bib21], [@bib25]) or animal model ([@bib18]). Interestingly, this locus is an intergenic sequence; thus, knockin of a transgene into the site does not induce the gene disruption observed with other safe harbor sites such as AAVS1 and the albumin locus. Using this advantage, we chose the *H11* locus to develop our universal correction platform via targeted integration of the *FVIII* gene. In addition, we used two types of patient iPSCs, FVIII inverted and large deleted patient iPSCs, for a proof of principle. In our experiments, we generated corrected clones with high efficiency in the two different types of iPSCs and demonstrated the functional recovery of mRNA expression as well as the secretion of the FVIII protein from the corrected cells *in vitro*. Nevertheless, the functional effects following transplantation in an *in vivo* system still need to be confirmed.

Off-target mutations are a concern regarding the therapeutic use of engineered nucleases. To avoid off-target effects, we chose unique target sequences that differed from any other site in the human genome by at least three nucleotides. We also used 5′-GGX~20~ sgRNAs transcribed *in vitro*, which reduced off-target mutations without reducing on-target activity as previously reported ([@bib3]), and electroporated Cas9 RNPs into the patient iPSCs ([@bib7]). In addition, targeted deep sequencing was performed to validate the absence of unwanted mutations in the corrected clones following the removal of the puromycin expression cassette, resulting in no off-target mutations. These results are consistent with previous reports of the reduced induction of off-target mutations in individual clones of edited cells ([@bib12], [@bib22]).

In summary, we used the *H11* locus to develop a universal correction platform, and precisely targeted the *FVIII* gene via error-free knockin with high efficiency. Finally, we verified that endothelial cells (ECs) successfully differentiated from the corrected iPSCs containing the *FVIII* gene and secreted functional protein *in vitro* system. This approach is not only simple but may also provide a universal platform to correct for the various mutations found in HA using the same sgRNA and donor DNA for one target site, the human *H11* locus.

Experimental Procedures {#sec4}
=======================

Ethical Statement {#sec4.1}
-----------------

The generation and analyses of iPSCs from the HA patients were approved by Yonsei University Institutional Review Board (IRB \#4-2012-0028). All volunteers who participated in this study signed written informed consent forms before donating cells for the generation of iPSCs.

Preparations of Donor Plasmid and Guide RNA for SpCas9 {#sec4.2}
------------------------------------------------------

To construct the donor plasmid, we used the pCDNA4/BDD-FVIII plasmid ([www.addgene.org](http://www.addgene.org){#intref0020}, no. 41035) ([@bib16]) as a backbone. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for details of the protocol.

Off-Target Analysis and Targeted Deep Sequencing {#sec4.3}
------------------------------------------------

Ten potential off-target sites differing by up to four nucleotides from the on-target site were searched using a web-based *in silico* tool ([crispr.mit.edu](http://crispr.mit.edu){#intref0025}) ([@bib17]). For deep sequencing analysis, PCR amplicons for each off-target site and the on-target site were prepared from genomic DNA using high-fidelity PrimeSTAR Max DNA polymerase (Takara Bio) and the specific primer sets listed in [Table S3](#mmc1){ref-type="supplementary-material"}. Following PCR purification of the resulting PCR products using an *AccuPrep* PCR Purification Kit (Bioneer, Korea), the PCR amplicons were subjected to paired-end sequencing using a MiSeq system (Illumina) at LAS (Korea).

CRISPR/Cas9-Mediated Correction by *FVIII* Knockin {#sec4.4}
--------------------------------------------------

Cas9 RNPs and *FVIII* knockin donor DNA were electroporated into the patient iPSCs as previously described ([@bib12]) with slight modifications. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for details of the protocol.

Excision of the Puromycin Selection Cassette {#sec4.5}
--------------------------------------------

To excise the puromycin expression cassette from the *FVIII* knockin clones, we electroporated 2 × 10^5^ knockin iPSCs with 1 μg of the *Cre* expression plasmid (pCAG-*Cre*:GFP; no. 13776, [www.addgene.org](http://www.addgene.org){#intref0030}). The isolation of clones was performed by single cell passaging as previously described ([@bib15]). The excision of the puromycin cassette was confirmed by PCR-based genotyping using the F3 and R2 primers. After removal of the puromycin expression cassette, we confirmed the absence of the *Cre* expression vector in each clone by PCR using the CRE-F and CRE-R primers listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

Differentiation into Endothelial Cells {#sec4.6}
--------------------------------------

To induce the differentiation of the iPSCs into ECs, we used a previously described protocol ([@bib5]) with slight modifications. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for details of the protocol.

Measurement of FVIII Activity {#sec4.7}
-----------------------------

To measure FVIII activity, we concentrated culture supernatants 20-fold using an Amicon Ultra-4 centrifugal filter (Millipore). The FVIII activities were measured in the culture supernatants using the commercially available Coamatic Factor VIII chromogenic assay kit (Instrumentation Laboratory) according to the manufacturer\'s instructions. See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for details of the protocol.

Statistical Analysis {#sec4.8}
--------------------

All data are expressed as means ± SEM of at least three independent experiments. Statistically significant differences were estimated using a Student\'s t test. A resulting p value of \<0.05 was considered statistically significant.
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Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S4, and Tables S1--S4Document S2. Article plus Supplemental Information

C.-Y.P. was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2016R1C1B1008742). D.-W.K. was supported by the Bio & Medical Technology Development Program of the NRF (2017M3A9B4042580), the Korea Health Technology R&D Project from the Ministry of Health and Welfare (HI18C0829), and the Faculty Research Grant of Yonsei University College of Medicine (6-2017-0190).

Supplemental Information can be found online at <https://doi.org/10.1016/j.stemcr.2019.04.016>.
